Evidence map›Paper›PMID 35077138›Full record

ReviewACS synthetic biology2022

Combating Infectious Diseases with Synthetic Biology.

Anooshay Khan, Julian Ostaku, Ebru Aras, Urartu Ozgur Safak Seker

Abstract readReview
In one paragraph

Review in ACS synthetic biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Synthetic toehold biosensors for detectingFrontiers in microbiology · 2026
    Article
  2. Golden Gate Cloning in Actinobacteria: Opportunities and Challenges.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Phage therapy: breathing new tactics into lower respiratory tract infection treatments.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anooshay KhanUNAM - National Nanotechnology Research Center, Institute of Materials Science and Nanotechnology Bilkent University, 06800 Ankara, Turkey.
Julian OstakuUNAM - National Nanotechnology Research Center, Institute of Materials Science and Nanotechnology Bilkent University, 06800 Ankara, Turkey.
Ebru ArasUNAM - National Nanotechnology Research Center, Institute of Materials Science and Nanotechnology Bilkent University, 06800 Ankara, Turkey.
Urartu Ozgur Safak SekerUNAM - National Nanotechnology Research Center, Institute of Materials Science and Nanotechnology Bilkent University, 06800 Ankara, Turkey.ORCID 0000-0002-5272-1876

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past decades, there have been numerous outbreaks, including parasitic, fungal, bacterial, and viral infections, worldwide. The rate at which infectious diseases are emerging is disproportionate to the rate of development for new strategies that could combat them. Therefore, there is an increasing demand to develop novel, specific, sensitive, and effective methods for infectious disease diagnosis and treatment. Designed synthetic systems and devices are becoming powerful tools to treat human diseases. The advancement in synthetic biology offers efficient, accurate, and cost-effective platforms for detecting and preventing infectious diseases. Herein we focus on the latest state of living theranostics and its implications.

Indexed as

Synthetic BiologyBacterial Physiological PhenomenaBacteriophagesCommunicable Disease ControlCOVID-19HumansPandemicsPrecision MedicineSARS-CoV-2diagnosticsengineered phage and bacteriainfectious diseasesSARS-CoV-2synthetic biologytherapeutics

Identifiers

PMID35077138
PMCPMC8895449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.